MediciNova reports 'positive' top-line results from MN-166 clinical trial
MediciNova announced positive top-line results from MediciNova's clinical trial of MN-166 in amyotrophic lateral sclerosis. Data analysis was conducted on the 51 subjects without non-invasive ventilation in the ITT population. The trial achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of MN-166. MN-166 demonstrated a favorable safety and tolerability profile. All subjects in the study received 100 mg of riluzole per day. There were 7 serious adverse events reported during the study but none of the SAEs were related to the study drug. All treatment-related adverse events were mild to moderate in intensity and no severe or life-threatening TRAEs were reported. The most frequently reported TRAEs were nausea, anorexia, and loss of appetite, which were expected and are common side effects of both riluzole treatment and MN-166 treatment. Dr. Benjamin Rix Brooks, principal investigator, commented, "The results of this study are very encouraging and indicate that MN-166 has the potential to stop disease progression and improve functional activity in some ALS patients. This is an impressive effect that has not been observed in studies of other drugs for ALS. We are excited to participate in the further development of MN-166 for this devastating disease."